8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 27, 2026·SEC
Material company update
Feb 5, 2026·SEC
Ocular Therapeutix, Inc.(OCUL)Earnings, Financials & Key Ratios
OCUL•NASDAQ
$9.71
$2.11B mkt cap·Price updated May 6, 2026
AboutOcular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Show more
- Revenue$52M-18.7%
- EBITDA-$266M-58.2%
- Net Income-$266M-37.4%
- EPS (Diluted)-1.42-16.4%
- Gross Margin87.31%-4.2%
- EBITDA Margin-512.7%-94.5%
- Operating Margin-521.04%-93.3%
- Net Margin-513.17%-69.0%
- ROE-54.85%+42.4%
- Debt/Equity0.12-49.3%
- Interest Coverage-21.47-62.0%
OCUL Key Insights
Ocular Therapeutix, Inc. (OCUL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 24.4%
✗Weaknesses
- ✗Profits declining 11.3% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 18.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OCUL Price & Volume
Ocular Therapeutix, Inc. (OCUL) stock price & volume — 10-year historical chart
Loading chart...
OCUL Growth Metrics
Ocular Therapeutix, Inc. (OCUL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years40.33%
5 Years24.39%
3 Years0.21%
TTM-12.76%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-50.74%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-26.96%
Return on Capital
10 Years-68.94%
5 Years-48.04%
3 Years-49.8%
Last Year-46.01%
OCUL Recent Earnings
Ocular Therapeutix, Inc. (OCUL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
May 5, 2026EPS
$0.41
Est $0.32
-28.1%
Revenue
$11M
Est $13M
-15.2%
Q1 2026
Feb 5, 2026EPS
$0.29
Est $0.33
+12.1%
Revenue
$13M
Est $16M
-17.8%
Q4 2025
Nov 4, 2025EPS
$0.37
Est $0.39
+5.1%
Revenue
$15M
Est $16M
-9.9%
Q3 2025
Aug 5, 2025EPS
$0.39
Est $0.35
-11.4%
Revenue
$13M
Est $15M
-7.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.41vs $0.32-28.1% | $11Mvs $13M-15.2% |
| Q1 2026 | Feb 5, 2026 | $0.29vs $0.33+12.1% | $13Mvs $16M-17.8% |
| Q4 2025 | Nov 4, 2025 | $0.37vs $0.39+5.1% | $15Mvs $16M-9.9% |
| Q3 2025 | Aug 5, 2025 | $0.39vs $0.35-11.4% | $13Mvs $15M-7.6% |
Based on last 12 quarters of dataView full earnings history →
OCUL Peer Comparison
Ocular Therapeutix, Inc. (OCUL) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 | |||
 KALA | 855.53K | 0.12 | -0.02 | -141.11% | -388.29% | 2.62 | ||
 ALDX | 104.68M | 1.74 | -1.85 | -87.71% | 0.22 | |||
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 SGHT | 232.23M | 4.30 | -5.81 | -3.13% | -46.83% | -59.1% | 0.64 | |
 LNTH | 5.61B | 86.15 | 25.26 | 0.5% | 15.15% | 20.58% | 0.00 | |
 RXST | 279.79M | 6.78 | -7.14 | -3.89% | -36.58% | -17.01% | 0.04 | |
 ATRC | 1.42B | 28.01 | -116.71 | 14.88% | -0.83% | -0.95% | 0.18 |
Compare OCUL vs Peers
Ocular Therapeutix, Inc. (OCUL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OCUL Income Statement
Ocular Therapeutix, Inc. (OCUL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.92M | 1.99M | 4.23M | 17.4M | 43.52M | 51.49M | 58.44M | 63.72M | 51.82M | 52.04M |
| Revenue Growth % | 1.91% | 3.48% | 112.41% | 311.71% | 150.08% | 18.32% | 13.49% | 9.03% | -18.67% | -12.76% |
| Cost of Goods Sold | 457K | 465K | 2.33M | 2.08M | 4.41M | 4.54M | 5.28M | 5.63M | 6.57M | 6.64M |
| COGS % of Revenue | 23.77% | 23.37% | 55% | 11.97% | 10.12% | 8.82% | 9.04% | 8.83% | 12.69% | - |
| Gross Profit | 1.47M▲ 0% | 1.52M▲ 4.0% | 1.9M▲ 24.7% | 15.32M▲ 705.5% | 39.12M▲ 155.3% | 46.95M▲ 20.0% | 53.16M▲ 13.2% | 58.1M▲ 9.3% | 45.25M▼ 22.1% | 45.4M▲ 0% |
| Gross Margin % | 76.23% | 76.63% | 45% | 88.03% | 89.88% | 91.18% | 90.96% | 91.17% | 87.31% | 87.24% |
| Gross Profit Growth % | 1.52% | 4.02% | 24.72% | 705.47% | 155.33% | 20.04% | 13.22% | 9.28% | -22.11% | - |
| Operating Expenses | 63.39M | 60.64M | 87.7M | 78.17M | 117.15M | 125.61M | 135.54M | 229.88M | 315.39M | 344.84M |
| OpEx % of Revenue | 3296.36% | 3047.39% | 2074.85% | 449.16% | 269.18% | 243.93% | 231.93% | 360.75% | 608.6% | - |
| Selling, General & Admin | 32.51M | 23.73M | 46.61M | 49.47M | 67.07M | 72.15M | 74.49M | 102.24M | 118.3M | 124.38M |
| SG&A % of Revenue | 1690.54% | 1192.36% | 1102.74% | 284.28% | 154.11% | 140.11% | 127.46% | 160.45% | 228.27% | - |
| Research & Development | 30.88M | 36.91M | 41.09M | 28.69M | 50.08M | 53.46M | 61.05M | 127.64M | 197.1M | 220.45M |
| R&D % of Revenue | 1605.82% | 1855.03% | 972.11% | 164.88% | 115.08% | 103.82% | 104.47% | 200.3% | 380.33% | - |
| Other Operating Expenses | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -61.92M▲ 0% | -59.12M▲ 4.5% | -85.8M▼ 45.1% | -62.85M▲ 26.8% | -78.04M▼ 24.2% | -78.65M▼ 0.8% | -82.38M▼ 4.7% | -171.78M▼ 108.5% | -270.02M▼ 57.2% | -299.44M▲ 0% |
| Operating Margin % | -3220.12% | -2970.75% | -2029.86% | -361.13% | -179.3% | -152.74% | -140.96% | -269.57% | -521.04% | -575.42% |
| Operating Income Growth % | -42.92% | 4.53% | -45.14% | 26.75% | -24.17% | -0.79% | -4.74% | -108.52% | -57.19% | - |
| EBITDA | -60.3M | -56.83M | -83.27M | -60.07M | -75.62M | -76.55M | -79.4M | -168M | -265.69M | -296.09M |
| EBITDA Margin % | -3135.62% | -2855.88% | -1970% | -345.19% | -173.74% | -148.65% | -135.86% | -263.63% | -512.7% | -569% |
| EBITDA Growth % | -42.06% | 5.75% | -46.52% | 27.86% | -25.87% | -1.23% | -3.73% | -111.58% | -58.16% | -47.87% |
| D&A (Non-Cash Add-back) | 1.63M | 2.29M | 2.53M | 2.77M | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M | 3.35M |
| EBIT | -61.49M | -58.24M | -80.27M | -148.87M | 118K | -64.02M | -69.4M | -179.93M | -254.1M | -193.04M |
| Net Interest Income | -1.47M | -860K | -4.87M | -6.6M | -6.64M | -6.22M | -7.36M | 6.71M | 6.52M | 5.68M |
| Interest Income | 424K | 879K | 1.23M | 168K | 33K | 798K | 3.98M | 20.28M | 18.36M | 20.58M |
| Interest Expense | 1.89M | 1.74M | 6.1M | 6.77M | 6.67M | 7.02M | 11.34M | 13.58M | 11.84M | 6.07M |
| Other Income/Expense | -1.46M | -860K | -570K | -92.79M | 71.48M | 7.62M | 1.65M | -21.73M | 4.08M | 8.94M |
| Pretax Income | -63.39M▲ 0% | -59.98M▲ 5.4% | -86.37M▼ 44.0% | -155.64M▼ 80.2% | -6.55M▲ 95.8% | -71.04M▼ 984.1% | -80.74M▼ 13.7% | -193.51M▼ 139.7% | -265.94M▼ 37.4% | -290.5M▲ 0% |
| Pretax Margin % | -3296.2% | -3013.97% | -2043.34% | -894.31% | -15.06% | -137.95% | -138.14% | -303.67% | -513.17% | -558.24% |
| Income Tax | 272K | -2.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.43% | 3.81% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -63.39M▲ 0% | -57.69M▲ 9.0% | -86.37M▼ 49.7% | -155.64M▼ 80.2% | -6.55M▲ 95.8% | -71.04M▼ 984.1% | -80.74M▼ 13.7% | -193.51M▼ 139.7% | -265.94M▼ 37.4% | -290.5M▲ 0% |
| Net Margin % | -3296.2% | -2899.1% | -2043.34% | -894.31% | -15.06% | -137.95% | -138.14% | -303.67% | -513.17% | -558.24% |
| Net Income Growth % | -41.79% | 8.98% | -49.71% | -80.19% | 95.79% | -984.05% | -13.65% | -139.68% | -37.43% | -50.74% |
| Net Income (Continuing) | -63.39M | -59.98M | -86.37M | -155.64M | -6.55M | -71.04M | -80.74M | -193.51M | -265.94M | -290.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.20▲ 0% | -1.57▲ 28.6% | -1.91▼ 21.7% | -2.56▼ 34.0% | -0.98▲ 61.7% | -0.97▲ 1.0% | -1.02▼ 5.2% | -1.22▼ 19.6% | -1.42▼ 16.4% | -1.30▲ 0% |
| EPS Growth % | -22.22% | 28.64% | -21.66% | -34.03% | 61.72% | 1.02% | -5.15% | -19.61% | -16.39% | -26.96% |
| EPS (Basic) | -2.20 | -1.57 | -1.91 | -2.56 | -1.05 | -1.04 | -1.09 | -1.22 | -1.42 | - |
| Diluted Shares Outstanding | 28.82M | 38.12M | 45.27M | 60.75M | 82.16M | 82.64M | 85.6M | 158.26M | 187.24M | 224.1M |
| Basic Shares Outstanding | 28.82M | 38.12M | 45.27M | 60.75M | 76.39M | 76.88M | 79.83M | 158.26M | 187.24M | 224.1M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
OCUL Balance Sheet
Ocular Therapeutix, Inc. (OCUL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 43.34M | 56.19M | 60.17M | 246.16M | 191.3M | 129.63M | 232.24M | 440.99M | 782.13M | 706M |
| Cash & Short-Term Investments | 41.54M | 54.06M | 54.44M | 228.06M | 164.16M | 102.3M | 195.81M | 392.1M | 737.06M | 666.7M |
| Cash Only | 41.54M | 54.06M | 54.44M | 228.06M | 164.16M | 102.3M | 195.81M | 392.1M | 737.06M | 666.7M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 226K | 201K | 2.55M | 12.25M | 21.14M | 21.32M | 26.18M | 32.39M | 30.65M | 24.35M |
| Days Sales Outstanding | 42.9 | 36.87 | 220.02 | 256.97 | 177.25 | 151.16 | 163.5 | 185.52 | 215.87 | 203.72 |
| Inventory | 122K | 217K | 954K | 1.2M | 1.25M | 1.97M | 2.31M | 3.04M | 3.56M | 3.74M |
| Days Inventory Outstanding | 97.44 | 170.33 | 149.77 | 210.45 | 103.55 | 158.7 | 159.31 | 197.23 | 197.88 | 190 |
| Other Current Assets | 108K | 1.71M | 0 | 0 | 0 | 4.03M | 7.94M | 13.46M | 10.86M | 11.21M |
| Total Non-Current Assets | 12.09M | 16.85M | 18.57M | 15.7M | 13.59M | 19.66M | 19.82M | 16.95M | 25.93M | 26.53M |
| Property, Plant & Equipment | 10.48M | 10.24M | 16.81M | 13.94M | 11.82M | 17.9M | 18.21M | 15.33M | 24.31M | 24.92M |
| Fixed Asset Turnover | 0.18x | 0.19x | 0.25x | 1.25x | 3.68x | 2.88x | 3.21x | 4.16x | 2.13x | 2.37x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.61M | 6.61M | 0 | 0 | 0 | 0 | 0 | 0 | 1.61M | 3.23M |
| Other Non-Current Assets | 0 | 0 | 1.76M | 1.76M | 1.76M | 1.76M | 1.61M | 1.61M | 0 | 3.23M |
| Total Assets | 55.43M▲ 0% | 73.04M▲ 31.8% | 78.74M▲ 7.8% | 261.86M▲ 232.6% | 204.89M▼ 21.8% | 149.29M▼ 27.1% | 252.06M▲ 68.8% | 457.94M▲ 81.7% | 808.06M▲ 76.5% | 732.53M▲ 0% |
| Asset Turnover | 0.03x | 0.03x | 0.05x | 0.07x | 0.21x | 0.34x | 0.23x | 0.14x | 0.06x | 0.09x |
| Asset Growth % | -26.03% | 31.77% | 7.8% | 232.57% | -21.76% | -27.14% | 68.84% | 81.68% | 76.46% | 127.99% |
| Total Current Liabilities | 13.43M | 9.16M | 12.03M | 26.66M | 26.34M | 31.39M | 34.9M | 41.35M | 50.81M | 47.68M |
| Accounts Payable | 3.57M | 2.96M | 3.27M | 2.71M | 4.59M | 5.12M | 4.39M | 4.18M | 4.15M | 8.03M |
| Days Payables Outstanding | 2.85K | 2.33K | 513.04 | 474.69 | 380.41 | 411.87 | 303.35 | 270.93 | 230.64 | 334.29 |
| Short-Term Debt | 5.54M | 0 | 0 | 8.29M | 0 | 0 | 0 | 0 | 2.82M | 3.17M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 576K | 255K | 128K | 0 | 14M |
| Other Current Liabilities | 1.37M | 2.64M | 0 | 0 | 0 | 0 | 0 | 0 | 25.86M | 22.49M |
| Current Ratio | 3.23x | 6.14x | 5.00x | 9.23x | 7.26x | 4.13x | 6.66x | 10.66x | 15.39x | 15.39x |
| Quick Ratio | 3.22x | 6.11x | 4.92x | 9.19x | 7.22x | 4.07x | 6.59x | 10.59x | 15.32x | 15.32x |
| Cash Conversion Cycle | -2.71K | -2.12K | -143.25 | -7.28 | -99.61 | -102.01 | 19.46 | 111.82 | 183.12 | 59.43 |
| Total Non-Current Liabilities | 15.86M | 28.01M | 70.34M | 159.1M | 90.55M | 82.52M | 126.03M | 101.24M | 102.94M | 103.27M |
| Long-Term Debt | 12.47M | 24.79M | 49.31M | 41.24M | 51.44M | 54.01M | 74.92M | 68.5M | 74.15M | 76.29M |
| Capital Lease Obligations | 0 | 0 | 8.9M | 7.55M | 5.92M | 8.68M | 6.88M | 5.34M | 2.81M | 10.85M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.39M | 3.22M | 12.12M | 98.31M | 20.19M | 6.44M | 30.09M | 13.39M | 11.97M | 71.06M |
| Total Liabilities | 29.28M | 37.17M | 82.37M | 185.77M | 116.89M | 113.91M | 160.93M | 142.59M | 153.75M | 150.96M |
| Total Debt | 18.02M | 24.79M | 59.34M | 58.44M | 58.98M | 64.28M | 83.39M | 75.78M | 79.78M | 79.46M |
| Net Debt | -23.52M | -29.27M | 4.91M | -169.62M | -105.18M | -38.02M | -112.42M | -316.32M | -657.28M | -587.24M |
| Debt / Equity | 0.69x | 0.69x | - | 0.77x | 0.67x | 1.82x | 0.92x | 0.24x | 0.12x | 0.12x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.27x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.98x |
| Interest Coverage | -32.50x | -33.49x | -13.16x | -22.00x | 0.02x | -9.12x | -6.12x | -13.25x | -21.47x | -31.79x |
| Total Equity | 26.15M▲ 0% | 35.88M▲ 37.2% | -3.63M▼ 110.1% | 76.09M▲ 2196.3% | 88M▲ 15.6% | 35.38M▼ 59.8% | 91.13M▲ 157.6% | 315.34M▲ 246.0% | 654.31M▲ 107.5% | 581.57M▲ 0% |
| Equity Growth % | -49.73% | 37.2% | -110.12% | 2196.28% | 15.64% | -59.8% | 157.59% | 246.03% | 107.49% | 180.54% |
| Book Value per Share | 0.91 | 0.94 | -0.08 | 1.25 | 1.07 | 0.43 | 1.06 | 1.99 | 3.49 | 2.60 |
| Total Shareholders' Equity | 26.15M | 35.88M | -3.63M | 76.09M | 88M | 35.38M | 91.13M | 315.34M | 654.31M | 581.57M |
| Common Stock | 3K | 4K | 5K | 8K | 8K | 8K | 12K | 16K | 22K | 22K |
| Retained Earnings | -237.26M | -297.24M | -383.62M | -539.25M | -545.8M | -616.84M | -697.58M | -891.08M | -1.16B | -1.25B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OCUL Cash Flow Statement
Ocular Therapeutix, Inc. (OCUL) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -50.47M | -49.23M | -77.58M | -53.55M | -65.55M | -59.6M | -70.23M | -134.68M | -204.88M | -204.88M |
| Operating CF Margin % | -2624.7% | -2473.72% | -1835.3% | -307.73% | -150.61% | -115.75% | -120.18% | -211.35% | -395.35% | - |
| Operating CF Growth % | -48.45% | 2.47% | -57.59% | 30.97% | -22.4% | 9.07% | -17.84% | -91.75% | -52.13% | -246.78% |
| Net Income | -63.39M | -59.98M | -86.37M | -155.64M | -6.55M | -71.04M | -80.74M | -193.51M | -265.94M | -290.5M |
| Depreciation & Amortization | 1.63M | 2.29M | 2.53M | 2.77M | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M | 4.63M |
| Stock-Based Compensation | 7.32M | 7.48M | 8.76M | 7.53M | 14.98M | 16.96M | 17.82M | 33.11M | 43.18M | 36.62M |
| Deferred Taxes | 9K | 0 | -4.3M | 86.19M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 408K | 397K | 3.68M | 4.41M | -73.49M | -8.99M | -2.9M | 32.16M | 5.84M | 20.87M |
| Working Capital Changes | 3.55M | 585K | -1.88M | 1.18M | -2.9M | 1.35M | -7.41M | -10.23M | 7.71M | 2.18M |
| Change in Receivables | 24K | 25K | -2.35M | -9.7M | -8.88M | -190K | -4.85M | -6.21M | 1.74M | 874K |
| Change in Inventory | -9K | -95K | -737K | -247K | -49K | -724K | -331K | -735K | -524K | -468K |
| Change in Payables | 932K | -796K | 124K | -452K | 1.8M | -621K | 583K | -318K | -887K | 2.83M |
| Cash from Investing | 27.07M | -1.89M | -2.24M | -841K | -1.19M | -3.71M | -6.09M | -1.29M | -11.88M | -14.61M |
| Capital Expenditures | -8.25M | -1.89M | -2.24M | -841K | -1.19M | -3.71M | -6.09M | -1.29M | -12.01M | -14.74M |
| CapEx % of Revenue | 429.12% | 94.92% | 52.95% | 4.83% | 2.74% | 7.21% | 10.42% | 2.02% | 23.18% | - |
| Acquisitions | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 114K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 130K | 130K |
| Cash from Financing | 32.01M | 68.64M | 75.34M | 228.01M | 2.85M | 1.45M | 169.83M | 332.11M | 561.72M | 557.83M |
| Debt Issued (Net) | 2.4M | 6.38M | 37.27M | 0 | -445K | 0 | 56.35M | 316.35M | 0 | 0 |
| Equity Issued (Net) | 29.24M | 61.57M | 37.54M | 224.68M | 985K | 940K | 118.11M | 316.35M | 561.72M | 557.54M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 370K | 694K | 529K | 3.33M | 2.31M | 514K | -4.63M | -300.6M | 0 | 294K |
| Net Change in Cash | 8.6M▲ 0% | 17.52M▲ 103.7% | -4.47M▼ 125.5% | 173.62M▲ 3979.8% | -63.89M▼ 136.8% | -61.86M▲ 3.2% | 93.51M▲ 251.1% | 196.15M▲ 109.8% | 344.96M▲ 75.9% | 317.02M▲ 0% |
| Free Cash Flow | -58.73M▲ 0% | -51.12M▲ 13.0% | -79.82M▼ 56.1% | -54.4M▲ 31.8% | -66.74M▼ 22.7% | -63.32M▲ 5.1% | -76.32M▼ 20.5% | -135.97M▼ 78.1% | -216.89M▼ 59.5% | -240.94M▲ 0% |
| FCF Margin % | -3053.82% | -2568.64% | -1888.24% | -312.56% | -153.36% | -122.96% | -130.59% | -213.37% | -418.53% | -463.02% |
| FCF Growth % | -63.49% | 12.96% | -56.15% | 31.85% | -22.7% | 5.13% | -20.54% | -78.15% | -59.52% | -62.33% |
| FCF per Share | -2.04 | -1.34 | -1.76 | -0.90 | -0.81 | -0.77 | -0.89 | -0.86 | -1.16 | -1.16 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.85x | 0.90x | 0.34x | 10.00x | 0.84x | 0.87x | 0.70x | 0.77x | 0.83x |
| Interest Paid | 0 | 0 | 0 | 0 | 1.93M | 2.15M | 5.46M | 0 | 0 | 2.24M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OCUL Key Ratios
Ocular Therapeutix, Inc. (OCUL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -162.21% | -186.04% | -535.72% | -429.55% | -7.99% | -115.16% | -127.64% | -95.21% | -54.85% | -64.55% |
| Return on Invested Capital (ROIC) | -248.75% | -961.16% | -1633.91% | - | - | - | - | - | - | 3070.22% |
| Gross Margin | 76.23% | 76.63% | 45% | 88.03% | 89.88% | 91.18% | 90.96% | 91.17% | 87.31% | 87.24% |
| Net Margin | -3296.2% | -2899.1% | -2043.34% | -894.31% | -15.06% | -137.95% | -138.14% | -303.67% | -513.17% | -558.24% |
| Debt / Equity | 0.69x | 0.69x | - | 0.77x | 0.67x | 1.82x | 0.92x | 0.24x | 0.12x | 0.12x |
| Interest Coverage | -32.50x | -33.49x | -13.16x | -22.00x | 0.02x | -9.12x | -6.12x | -13.25x | -21.47x | -31.79x |
| FCF Conversion | 0.80x | 0.85x | 0.90x | 0.34x | 10.00x | 0.84x | 0.87x | 0.70x | 0.77x | 0.83x |
| Revenue Growth | 1.91% | 3.48% | 112.41% | 311.71% | 150.08% | 18.32% | 13.49% | 9.03% | -18.67% | -12.76% |
OCUL SEC Filings & Documents
Ocular Therapeutix, Inc. (OCUL) SEC filings — annual & quarterly reports (10-K, 10-Q)
OCUL Frequently Asked Questions
Ocular Therapeutix, Inc. (OCUL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ocular Therapeutix, Inc. (OCUL) reported $52.0M in revenue for fiscal year 2025. This represents a 520280% increase from $0.0M in 2012.
Ocular Therapeutix, Inc. (OCUL) saw revenue decline by 18.7% over the past year.
Ocular Therapeutix, Inc. (OCUL) reported a net loss of $290.5M for fiscal year 2025.
Dividend & Returns
Ocular Therapeutix, Inc. (OCUL) has a return on equity (ROE) of -54.9%. Negative ROE indicates the company is unprofitable.
Ocular Therapeutix, Inc. (OCUL) had negative free cash flow of $240.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More OCUL
Ocular Therapeutix, Inc. (OCUL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates